HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation
Amer M. Zeidan(Yale Cancer Center), Javier Bolaños‐Meade(Johns Hopkins University), Leo Luznik(Sidney Kimmel Comprehensive Cancer Center), Hetty E. Carraway(Cleveland Clinic), Richard J. Jones(Sidney Kimmel Cancer Center), Benjamin D. Smith(The University of Texas MD Anderson Cancer Center), Keith W. Pratz(Cancer Institute (WIA)), Patrick M. Forde(Johns Hopkins University), Ephraim J. Fuchs(Johns Hopkins Hospital), Douglas E. Gladstone(Northwell Health), Allen Chen(Johns Hopkins University), Heather J. Symons(Johns Hopkins University)
Cited by 113
Related Papers
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
|Cancer Research|2014|7.2k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
|Cancer Discovery|2016|897